Genentech - Business Information

Q: What industry does Genentech belong to?

Genentech is in the industry of: Business Services General , Business Services

Q: What is Genentech competition?

Genentech top competitors include: Biogen , Amgen Inc , CSL Ltd , Gilead Sciences Inc

Business Services · California, United States · 13,500 Employees

Founded more than 30 years ago, Genentech (gene.com) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.Read More

View Company Info for Free

Who is Genentech

Headquarters

1 Dna Way, South San Francisco, California, 94080, United States

Phone Number

(650) 225-1000

Website

www.gene.com

Revenue

$2.9B

Industry

Business Services General

Business Services

Is this data correct?

View contact profiles from Genentech

Popular SearchesGENENTECH IncGenentechGenentech USA IncGene Pharmaceuticals LLCGenentech FoundationSIC Code 28,283NAICS Code 32,325Show More

Top Competitors of Genentech

Biogen
9,090
$10.2B
1
Amgen Inc
25,200
$26.3B
2
CSL Ltd
25,000
$10.6B
3
Gilead Sciences Inc
14,400
$27.5B
4
Regeneron Pharmaceuticals Inc
11,851
$12.2B
5
Bristol-Myers Squibb Co
32,200
$47B
6

Compare CEO

How does Alexander Hardy compare against Competing Companies' CEOs?

Alexander Hardy

Chief Executive Officer at Genentech

Top 5%

CEO effectiveness to drive business results

Excellent

Good

66%

Average

33%

Poor

Very Bad

CEO management style

Good

66%

Bad

33%

VS.

Rob Davis

CEO at Merck

Top 15%

CEO effectiveness to drive business results

Excellent

50%

Good

Average

50%

Poor

Very Bad

CEO management style

Good

75%

Bad

25%

Select a different CEO to compare

Rob Davis

CEO at Merck

Albert Bourla

CEO at Pfizer

Karen S. Lynch

CEO at CVS Health

Genentech Org Chart

Alexander Hardy

Chief Executive Officer

Phone

Tersia Pillay

Chief of Staff & Director, O...

Phone

Sean Johnston

Senior VP, General Counsel &...

Phone

Genentech Email Formats

Genentech uses at least 5 email formats with last.first (ex. Smith.John@gene.com) being used 64.4% of the time

Genentech Email Formats		Percentage
last.first	Smith.John@gene.com	64.4%
last + first initials	SmithJ@gene.com	7.9%
first.last	John.Smith@gene.com	0%
first + last	JohnSmith@gene.com	0%
first_last	John_Smith@gene.com	0%

Get Verified Emails

View Email Formats for Genentech

Genentech Company Metrics

Company Insights

Employee Growth Rate

Funding

Funding DateJun 30, 1976

RoundUnspecified

Amount$100M

InvestorsKleiner Perkins Caufield & Byers

$100M

Total Funding Amount

$100M

Most Recent Funding Amount

Number of Funding Rounds

Acquisitions & Subsidiaries

Jul 18, 2022

TissueInformatics

Jul 18, 2022

GenMark Diagnostics

Apr 10, 2021

Ventana Medical Systems

May 21, 2018

OncoCloud

Dec 06, 2016

Jecure Therapeutics

Sep 26, 2016

Good Therapeutics

See More Acquisitions & Subsidiaries

Genentech Tech Stack

FedEx

Salesforce Live Agent

Salesforce

Google Global Site Tag

Google

Digital Insight

NCR

See more technologies

Top Companies in United States

Genentech News & Media

Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new data for Ocrevus® (ocrelizumab) and investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib for multiple sclerosis (MS), and Enspryng® (satralizumab) for neuromyelitis optica spectrum disorder (NMOSD). In total, Genentech will be presenting 36 abstracts at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Resear
Oct 2, 2023
www.businesswire.com
Chronic Obstructive Pulmonary Disease Market to Witness Upsurge in Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Companies - Genentech, GlaxoSmithKline, Regeneron, Sanofi, AstraZeneca, Mereo, Inmunotek
The dynamics of the chronic obstructive pulmonary disease market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies. The dynamics of the chronic obstructive pulmonary disease market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremen
Sep 25, 2023
www.globenewswire.com
PeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide-Radioisotope Drug Conjugates
KAWASAKI, Japan--(BUSINESS WIRE)--Combining the PeptiDream's expertise in the field of peptide-RI conjugates, with Genentech's powerful development and commercialization capabilities.
Sep 20, 2023
www.businesswire.com
Acute Respiratory Distress Syndrome Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Leading Companies to Watch Out - MediciNova, Mesoblast, Veru, Pluristem, Avalo, Boehringer Ingelheim, Genentech, Windtree
The acute respiratory distress syndrome market size shall grow during the forecast period (2023–2032) owing to the launch of upcoming therapies and is expected to increase at a significant rate during the study period. In the year 2021, the US contributed approximately USD 772.3 million (65.8%) to the total ARDS market size in the 7MM. The acute respiratory distress syndrome market size shall grow during the forecast period (2023–2032) owing to the launch of upcoming
Sep 13, 2023
www.globenewswire.com
FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for crovalimab, an investigational, novel anti-C5 recycling monoclonal antibody, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The acceptance was based on results from the pivotal Phase III COMMODORE 2 study, which demonstrated that in pe
Sep 6, 2023
www.businesswire.com